No annual revenue total was found in VAXCYTE, INC.'s SEC filings.
Vaxcyte, Inc. (PCVX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$669.3 million. As of Sep 30, 2026 it held $2.3 billion in cash and investments and $221.8 million in total debt.
Revenue
—
Net income (TTM)
$-1.15B
-74.8% vs year-ago TTM
Operating cash flow (TTM)
$-962.01M
-77.4% vs year-ago TTM
Free cash flow (TTM)
$-974.42M
-74.9% vs year-ago TTM
EPS (TTM)
$-8.07
-66.7% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
143.92M
+11.8% vs prior year
Net cash
$2.04B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PCVX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1649094
- Former names
- SutroVax, Inc. (until Apr 3, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| Diluted EPS | -$5.63 | -$3.80 | -$4.14 | -$3.44 | — |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M | $284.0M |
| Cash and investments | $2.4B | $3.1B | $1.2B | $957.9M | $273.1M |
| Total debt | $117.6M | $71.1M | $29.2M | $17.9M | $16.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 3, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 767 Vaxcyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.